Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.

摘要: BACKGROUND: Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) are present approximately 30% to 40% of colorectal adenocarcinomas. Wild-type (WT) KRAS mutation status is predictive tumor response with epidermal growth factor receptor-directed therapies, but results from studies evaluating prognostic value localized disease have been contradictory. The metastatic disease, specifically according whether patients synchronous or metachronous at presentation, less understood. METHODS: One-hundred ten consecutive adenocarcinoma underwent testing for exon 2 mutations by polymerase chain reaction amplification and direct nucleotide sequencing. clinical characteristics, treatments, outcomes these were then analyzed retrospectively, stratified presented metastasis (WT mutated). RESULTS: For entire cohort, median overall survival date diagnosis was 34.3 months (95% confidence interval, 28.3-49.4 months) WT (n = 70). mutated 40) 40.3 27.9-51.1 months; log-rank P .91). Kaplan-Meier analysis indicated that 3-year 5-year not statistically different. Within subgroups no significant differences observed survival, between groups. CONCLUSIONS: In this study, did influence either and, as such, had role setting. Cancer 2012. © 2012 American Society.